![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/Endeavor_shutterstock_1682639740-430x241.jpg)
Endeavor BioMedicines has revealed results from the Phase IIa clinical trial where ENV-101 demonstrated to improve lung function in idiopathic pulmonary fibrosis (IPF) patients.
ENV-101 is engineered to inhibit the Hedgehog (Hh) pathway, which is overactive in fibrotic lung diseases and leads to the progressive accumulation of scar tissue.
The double-blind, randomised, placebo-controlled study assessed the safety and efficacy of ENV-101 compared to a placebo in 41 IPF patients.
Conducted across 16 sites in five countries, participants were assigned to receive either a 200mg dose of ENV-101 or a placebo daily for 12 weeks.
In September last year, the company concluded subject enrolment in the Phase IIa trial of ENV-101 (taladegib) to treat IPF.
The trial’s primary goal was to evaluate the safety of ENV-101.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
![](/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMeasuring changes in lung function from the trial’s start to week 12 alongside patient-reported outcomes from the UCSD shortness-of-breath questionnaire were the trial’s secondary endpoints.
The results showed that ENV-101 led to significant improvements in lung function and reversed key fibrosis markers over the trial period.
Patients treated with the therapy exhibited a statistically significant mean improvement in per cent predicted FVC (ppFVC) of 1.9% from baseline, compared to a mean decline of 1.3% in the placebo group.
Additionally, ENV-101 recipients saw a significant increase in total lung capacity (TLC) by a mean increase of 200mL at 12 weeks, against a mean decrease of 56mL for those on placebo.
In the ENV-101 group, 80% of patients experienced a TLC increase while 70% of placebo recipients saw a decrease.
The treatment also significantly reduced the absolute percent of quantitative interstitial lung disease (QILD) by 9.4% from baseline, compared to a 1.1% increase in the placebo group (P<0.05).
ENV-101 was found to be well-tolerated in the trial without any serious adverse events, grade 3 or 4 adverse events, or significant safety concerns.
Dysgeusia, alopecia and muscle spasms were reported to be the most frequently seen mild to moderate adverse events linked to ENV-101.
Endeavor BioMedicines chief medical officer Paul Frohna said: “These trial results suggest ENV-101 could have transformational clinical benefits for individuals with IPF, who are in need of therapies that change treatment expectations – from slowing disease progression to potentially reversing it. “We look forward to further evaluating ENV-101’s potential in the upcoming WHISTLE-PF clinical trial.”